glp-1 drugs impact on energy levels Frontiers Frontiers | GLP-1 agonists and

doi: 10.1185/03007995.2010.549466 166 HamiltonAPattersonSPorterDGaultVAHolscherC

6 Kidney disease is common among individuals with type 2 diabetes, as high blood sugar damages kidney blood vessels

However, clinical trials and real-world evidence consistently show that weight reduction with GLP-1RAs is accompanied by decrease in lean body mass, raising concern in patients already predisposed to muscle wasting and underscoring the need for integrated management strategies

By activating these two systems simultaneously, tirzepatide may help support improved blood sugar control while also helping patients feel fuller for longer periods of time

This distribution has prompted researchers to investigate whether GLP-1 receptor agonists might offer neuroprotective effects beyond their established metabolic benefits

Ribeiro-Silva JC, Tavares CAM, Girardi ACC